> Chutes & Ladders: NitroMed has named Kenneth Bate as its new CEO. Release
> Researchers say that updated data from an early-stage trial shows that IPI-504--being developed by Infinity Pharmaceuticals and Medimmune--cut the metabolic rate of tumors. Report
> The FDA has granted Chelsea Therapeutics orphan drug status for Droxidopa, a therapy for symptomatic neurogenic orthostatic hypotension. Release
> Avalon Pharmaceuticals has raised $10 million through a private placement. Release
> Atrium Biotechnologies is buying AquaCap Pharmaceutical for $21.5 million. AquaCap makes liquid filled capsules for the nutritional supplement market. Release
> The FDA has given fast track status to Sequella's SQ109, its lead drug candidate for treatment of pulmonary tuberculosis. Release
> Molecular Insight Pharmaceuticals has priced its IPO of 5 million shares at $14 to $16 a share. Report
> New data on Xeloda backs its use against colorectal cancer. Release
And Finally... British researchers say that a healthier lifestyle is as effective as drugs in preventing type 2 diabetes. Release